BACKGROUND: Few clinical trials have investigated the prevention of radiographic progression in children with juvenile idiopathic arthritis treated with antirheumatic drugs. This study aimed to investigate radiographic progression in patients with systemic juvenile idiopathic arthritis (sJIA) and patients with polyarticular-course juvenile idiopathic arthritis (pcJIA) treated with the anti-interleukin-6 receptor antibody tocilizumab for 2 years in the TENDER and CHERISH randomized controlled trials, respectively. METHODS: Standard radiographs of both wrists and both hands in the posteroanterior view were obtained within 4 weeks of baseline and were repeated at weeks 52 ± 4 and 104 ± 4 in both trials. All films were scored by two independent readers using the adapted Sharp-van der Heijde (aSH) and Poznanski scoring methods. Although the Poznanski score indicates bone growth limitation or cartilage growth decrease, which are not the same as joint space narrowing in rheumatoid arthritis, its change reflects damage to cartilage. Therefore, impairment in the Poznanski score as well as the aSH score was considered as a measure of structural joint damage. Radiographic progression was defined as worsening of radiographic scores beyond the smallest detectable difference. RESULTS: Poznanski and aSH scores were available at baseline and at one or more postbaseline time points for 33 and 47 of 112 sJIA patients and 61 and 87 of 188 pcJIA patients, respectively, providing a representative subset of the study populations. The inter-reader and intra-reader agreement intra-class correlation coefficient was > 0.8. Median baseline Poznanski and aSH scores, respectively, were - 2.4 and 24.6 for sJIA patients and - 1.5 and 8.0 for pcJIA patients. Compared with baseline, aSH scores remained stable for all sJIA patients at week 52, whereas 9.4% of sJIA patients had radiographic progression according to Poznanski scores at week 52; at 104 weeks, radiographic progression according to aSH and Poznanski scores was observed in 5.4% and 11.5%, respectively. In pcJIA patients, radiographic progression from baseline at 52 weeks and at 104 weeks was 12.5% and 2.9%, respectively, using aSH scoring and 6.5% and 4%, respectively, using Poznanski scoring. CONCLUSION: Tocilizumab may delay radiographic progression in children with sJIA and children with pcJIA. TRIAL REGISTRATION: Trial registration numbers and dates: TENDER, NCT00642460 (March 19, 2008); CHERISH, NCT00988221 (October 1, 2009).

Cincinnati Children's Hospital Medical Center Cincinnati OH USA

General University Hospital and 1st Faculty of Medicine Charles University Prague Czech Republic

Hospital Sor Maria Ludovica La Plata Argentina

IRCCS Istituto Giannina Gaslini Clinica Pediatrica e Reumatologia PRINTO Via G Gaslini 5 16147 Genoa Italy

IRCCS Istituto Giannina Gaslini Servizio di Epidemiologia e Biostatistica Genoa Italy

IRCCS Ospedale Pediatrico Bambino Gesú Rome Italy

Oslo University Hospital and University of Oslo Oslo Norway

Roche Products Ltd Welwyn Garden City UK

Sechenov 1st Moscow State Medical University Moscow Russian Federation

Università degli Studi di Genova Genoa Italy

University Hospital Gasthuisberg Leuven Belgium

Zobrazit více v PubMed

Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390–392. PubMed

Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369(9563):767–778. doi: 10.1016/S0140-6736(07)60363-8. PubMed DOI

Oen K, Reed M, Malleson PN, Cabral DA, Petty RE, Rosenberg AM, et al. Radiologic outcome and its relationship to functional disability in juvenile rheumatoid arthritis. J Rheumatol. 2003;30(4):832–840. PubMed

Ravelli A. The time has come to include assessment of radiographic progression in juvenile idiopathic arthritis clinical trials. J Rheumatol. 2008;35(4):553–557. PubMed

van Rossum MA, Zwinderman AH, Boers M, Dijkmans BA, van Soesbergen RM, Fiselier TJ, et al. Radiologic features in juvenile idiopathic arthritis: a first step in the development of a standardized assessment method. Arthritis Rheum. 2003;48(2):507–515. doi: 10.1002/art.10783. PubMed DOI

Magni-Manzoni S, Rossi F, Pistorio A, Temporini F, Viola S, Beluffi G, et al. Prognostic factors for radiographic progression, radiographic damage, and disability in juvenile idiopathic arthritis. Arthritis Rheum. 2003;48(12):3509–3517. doi: 10.1002/art.11337. PubMed DOI

Doria AS, de Castro CC, Kiss MH, Sernik RA, Vitule LF, Silva CH, et al. Inter- and intrareader variability in the interpretation of two radiographic classification systems for juvenile rheumatoid arthritis. Pediatr Radiol. 2003;33(10):673–681. doi: 10.1007/s00247-003-0912-y. PubMed DOI

Mason T, Reed AM, Nelson AM, Thomas KB. Radiographic progression in children with polyarticular juvenile rheumatoid arthritis: a pilot study. Ann Rheum Dis. 2005;64(3):491–493. doi: 10.1136/ard.2003.017053. PubMed DOI PMC

van Rossum MA, Boers M, Zwinderman AH, van Soesbergen RM, Wieringa H, Fiselier TJ, et al. Development of a standardized method of assessment of radiographs and radiographic change in juvenile idiopathic arthritis: introduction of the Dijkstra composite score. Arthritis Rheum. 2005;52(9):2865–2872. doi: 10.1002/art.21247. PubMed DOI

Rossi F, Di Dia F, Galipò O, Pistorio A, Valle M, Magni-Manzoni S, et al. Use of the Sharp and Larsen scoring methods in the assessment of radiographic progression in juvenile idiopathic arthritis. Arthritis Rheum. 2006;55(5):717–723. doi: 10.1002/art.22246. PubMed DOI

Ravelli A, Ioseliani M, Norambuena X, Sato J, Pistorio A, Rossi F, et al. Adapted versions of the Sharp/van der Heijde score are reliable and valid for assessment of radiographic progression in juvenile idiopathic arthritis. Arthritis Rheum. 2007;56(9):3087–3095. doi: 10.1002/art.22835. PubMed DOI

Rodriguez-Lozano AL, Giancane G, Pignataro R, Viola S, Valle M, Gregorio S, et al. Agreement among musculoskeletal pediatric specialists in the assessment of radiographic joint damage in juvenile idiopathic arthritis. Arthritis Care Res. 2014;66(1):34–39. doi: 10.1002/acr.22145. PubMed DOI

Harel L, Wagner-Weiner L, Poznanski AK, Spencer CH, Ekwo E, Magilavy DB. Effects of methotrexate on radiologic progression in juvenile rheumatoid arthritis. Arthritis Rheum. 1993;36(10):1370–1374. doi: 10.1002/art.1780361007. PubMed DOI

Ravelli A, Viola S, Ramenghi B, Beluffi G, Zonta LA, Martini A. Radiologic progression in patients with juvenile chronic arthritis treated with methotrexate. J Pediatr. 1998;133(2):262–265. doi: 10.1016/S0022-3476(98)70231-8. PubMed DOI

Nielsen S, Ruperto N, Gerloni V, Simonini G, Cortis E, Lepore L, et al. Preliminary evidence that etanercept may reduce radiographic progression in juvenile idiopathic arthritis. Clin Exp Rheumatol. 2008;26(4):688–692. PubMed

Aoki C, Inaba Y, Choe H, Kaneko U, Hara R, Miyamae T, et al. Discrepancy between clinical and radiological responses to tocilizumab treatment in patients with systemic-onset juvenile idiopathic arthritis. J Rheumatol. 2014;41(6):1171–1177. doi: 10.3899/jrheum.130924. PubMed DOI

Nishimoto N, Kishimoto T. Humanized antihuman IL-6 receptor antibody, tocilizumab. Handb Exp Pharmacol. 2008;181:151–160. doi: 10.1007/978-3-540-73259-4_7. PubMed DOI

Mihara M, Kasutani K, Okazaki M, Nakamura A, Kawai S, Sugimoto M, et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol. 2005;5(12):1731–1740. doi: 10.1016/j.intimp.2005.05.010. PubMed DOI

De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2385–2395. doi: 10.1056/NEJMoa1112802. PubMed DOI

Brunner HI, Ruperto N, Zuber Z, Keane C, Harari O, Kenwright A, et al. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis. 2014;74(6):1110–1117. doi: 10.1136/annrheumdis-2014-205351. PubMed DOI PMC

Actemra (tocilizumab) injection for intravenous or subcutaneous use [prescribing information]. South San Francisco: Genentech Inc.; 2018.

Fleischmann RM, Halland AM, Brzosko M, Burgos-Vargas R, Mela C, Vernon E, et al. Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year results. J Rheumatol. 2013;40(2):113–126. doi: 10.3899/jrheum.120447. PubMed DOI

Kremer JM, Blanco R, Brzosko S, Burgos-Vargas R, Halland AM, Vernon E, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum. 2011;63(3):609–621. doi: 10.1002/art.30158. PubMed DOI

Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x-ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis. 2007;66(9):1162–1167. doi: 10.1136/ard.2006.068064. PubMed DOI PMC

Inaba Y, Ozawa R, Imagawa T, Mori M, Hara Y, Miyamae T, et al. Radiographic improvement of damaged large joints in children with systemic juvenile idiopathic arthritis following tocilizumab treatment. Ann Rheum Dis. 2011;70(9):1693–1695. doi: 10.1136/ard.2010.145359. PubMed DOI

Ruperto N, Martini A. Networking in paediatrics: the example of the Paediatric Rheumatology International Trials Organisation (PRINTO) Arch Dis Child. 2011;96(6):596–601. doi: 10.1136/adc.2010.188946. PubMed DOI

Poznanski AK, Hernandez RJ, Guire KE, Bereza UL, Garn SM. Carpal length in children—a useful measurement in the diagnosis of rheumatoid arthritis and some congenital malformation syndromes. Radiology. 1978;129(3):661–668. doi: 10.1148/129.3.661. PubMed DOI

Lassere M, Boers M, van der Heijde D, Boonen A, Edmonds J, Saudan A, et al. Smallest detectable difference in radiological progression. J Rheumatol. 1999;26(3):731–739. PubMed

Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40(7):1202–1209. doi: 10.1002/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R. PubMed DOI

Oen K. Long-term outcomes and predictors of outcomes for patients with juvenile idiopathic arthritis. Best Pract Res Clin Rheumatol. 2002;16(3):347–360. doi: 10.1053/berh.2002.0233. PubMed DOI

Ravelli A. Toward an understanding of the long-term outcome of juvenile idiopathic arthritis. Clin Exp Rheumatol. 2004;22(3):271–275. PubMed

Levinson JE, Wallace CA. Dismantling the pyramid. J Rheumatol Suppl. 1992;33:6–10. PubMed

Cassone R, Falcone A, Rossi F, Magni-Manzoni S, Felici E, Buoncompagni A, et al. Unilateral destructive wrist synovitis in juvenile idiopathic arthritis. Clin Exp Rheumatol. 2004;22(5):637–642. PubMed

Remy A, Combe B. Repair of radiographic hip joint in juvenile rheumatoid arthritis patients treated with etanercept plus methotrexate. Joint Bone Spine. 2014;81(5):447–449. doi: 10.1016/j.jbspin.2014.03.006. PubMed DOI

Giancane G, Pederzoli S, Norambuena X, Ioseliani M, Sato J, Gallo MC, et al. Frequency of radiographic damage and progression in individual joints in children with juvenile idiopathic arthritis. Arthritis Care Res. 2014;66(1):27–33. doi: 10.1002/acr.22123. PubMed DOI

Zobrazit více v PubMed

ClinicalTrials.gov
NCT00642460, NCT00988221